Pharma.Aero Puts Accountability First in Pharma AI Debate

It sets out a five-level maturity model and treats accountability for AI decisions as non-transferable.

NAP strategic partner Pharma.Aero has released an industry opinion paper examining how artificial intelligence should be governed in pharmaceutical and MedTech supply chains.

From Capability to Accountability asks which decisions can responsibly be delegated to AI systems and under what conditions. It considers current uses of AI, the shift from human execution to oversight, and the role of trust, explainability and accountability in a regulated operating environment.

The paper also introduces a five-level maturity model built around technology and data, human capability, and governance and compliance. It treats accountability as non-transferable: organizations and people remain responsible for decisions supported by AI.

For pharma logistics members and partners, the framework offers a useful way to test whether an AI application is operationally valuable and whether the organization using it can remain accountable for the resulting decisions.

Sources: Pharma.Aero industry opinion paper and Pharma.Aero LinkedIn post